Astra returns research project to Allelix

Report this content

ASTRA RETURNS RESEARCH PROJECT TO ALLELIX Astra AB has decided to return all rights pertaining to ALX1-11, a recombinant parathyriod hormone (PTH) for treatment of osteoporosis, to Allelix Biopharmaceuticals Inc., Canada. "Astra evaluates all research projects on a continuous basis. Due to new opportunities that have been identified in other therapeutic areas, this project does not have the same priority as earlier," comments Claes Wilhelmsson, Executive Vice President, R&D, at Astra. Contact persons: Mikael Widell, Press Officer, PR & Information, Astra AB, +46 8 553 264 28 Jörgen Winroth, Investor Relations U.S., Astra AB, +1 609 896 4148

Documents & Links